On July 14, 2022 EVERSANA and Compai Pharma, a full-service commercialization company with offices in Singapore and Malaysia, reported a strategic partnership to expand services across the Asia Pacific region (Press release, EVERSANA, JUL 14, 2022, View Source [SID1234617514]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The partnership will provide medical and commercial resources to healthcare partners to support full market implementation and development for life science and pharmaceutical companies ready to expand into these markets.

EVERSANA CEO Jim Lang commented: "The Asia Pacific region is one of the fastest-growing pharmaceutical markets in the world and requires regional expertise to increase patient access. Together with Compai Pharma, we’re now able to drive greater value and services for our clients to support their evolving commercialization needs."

Capabilities available through the partnership include consulting, market access, medical awareness, education and communication, pharmacovigilance, marketing & sales excellence, as well as distribution and additional services.

The partnership with Compai builds on EVERSANA’s continued global growth, including recent expansion across the European Union and the UK. Additionally in June 2021, EVERSANA announced the growth of its medical communications and integrated compliance services across 18 European countries and in 10 local languages.

On July 14, 2022 Major shareholders of Prestige Biopharma Group were actively defending their stock prices, while the local stock market reported that it has recently fluctuated and fallen sharply due to concerns over an economic slowdown (Press release, Prestige BioPharma, JUL 14, 2022, View Source [SID1234616867]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

According to the Data Analysis Retrieval and Transfer System by Korean Financial Supervisory Service on July 14, Octava Fund Limited, a major institutional shareholder, recently purchased KRW 1.3 billion of Prestige Biopharma stock and KRW 400 million of Prestige Biologics stock, amounting to a total of KRW 1.7 billion.

Chairman Lisa S. Park and Vice Chairman Michael J. Kim of Prestige Biopharma Group, the largest shareholders of the two companies, have also bought a total of KRW 7.5 billion worth of stock through Mason Partners, a joint investment company established by Chairman Park and Vice Chairman Kim. As a result, the investment that major shareholders have put in defending the stock price of Prestige Biopharma and Prestige Biologics amounts to nearly KRW 10 billion since EMA.

According to the company, Octava Fund has provided support in defending the stock price to show trust and confidence as a long-term investment partner. Previously, the major institutional shareholder had purchased KRW 6.9 billion stock in December 2021.

Meanwhile, Prestige BioPharma is focusing on preparing for the re-examination of Marketing Authorisation Application (MAA) for the company’s Herceptin biosimilar HD201 that it requested European Medicines Agency (EMA) in May. The company decided to seek approval through re-examination by setting up with a global expert team, instead of choosing withdrawal and reapplication which will take more than a year. Prestige Biologics is strengthening its business with signing new contracts as a global CDMO utilizing its global-scale facilities and state-of-the-art patented technologies.

On July 14, 2022 HTG Molecular Diagnostics, Inc. (the "Company") reported that entered into an amendment (the "Amendment") to its Loan and Security Agreement, dated June 24, 2020, by and between the Company and Silicon Valley Bank (the "Loan Agreement") (Filing, 8-K, HTG Molecular Diagnostics, JUL 14, 2022, View Source [SID1234616729]). Under the Loan Agreement, Silicon Valley Bank provided the Company with a $10.0 million principal amount secured term loan (the "Term Loan"), of which $7.5 million remained outstanding as of June 30, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pursuant to the Amendment, the Company and Silicon Valley Bank agreed to remove the financial covenant under the Loan Agreement that had required the Company to maintain unrestricted cash, including short term investments available-for-sale, of not less than the greater of (i) $12.5 million and (ii) an amount equal to six times the amount of the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months. In exchange for this accommodation, the Company prepaid $2.5 million of outstanding principal under the Term Loan (the "Prepayment"). Silicon Valley Bank waived the prepayment fee that otherwise would have applied to the Prepayment. The remaining outstanding principal amount under the Term Loan will continue to be paid in equal monthly payments of principal and interest through the maturity date of December 1, 2023.

On July 14, 2022 West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, reported that it will release second-quarter 2022 financial results before the market opens on Thursday, July 28, 2022, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time (Press release, West Pharmaceutical Services, JUL 14, 2022, View Source [SID1234616708]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live audio-only webcast will be made available via the Company’s Investor Relations website https://bit.ly/3cgSM9S or by clicking here.

To participate in the conference call by asking questions to Management, please register in advance at https://bit.ly/3z4iU0g. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that will be used to access the call.

Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the presentation, select "Presentations" in the "Investors" section of the Company’s website.

A replay of the conference call and webcast will be available on the Company’s website for 30 days.

On July 14, 2022 Labcorp (NYSE: LH), a leading global life sciences company, reported that it will release its financial results for the second quarter of 2022 before the market opens on Thursday, July 28, 2022 (Press release, LabCorp, JUL 14, 2022, View Source [SID1234616699]). The company will host a conference call and webcast beginning at 9 a.m. EDT that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access the conference call by dialing 1-800-715-9871 within the U.S. and Canada, or 1-646-307-1963 internationally, using the conference ID 4124787. In addition, a real-time webcast of the conference call will be available on the Labcorp Investor Relations website.

An audio replay of the conference call will be available from 2 p.m. EDT on July 28, 2022, until 11:30 p.m. EDT on August 11, 2022, by dialing 1-800-770-2030 within the U.S. and Canada, or 1-609-800-9909 internationally, using the conference ID 4124787. The webcast of the conference call will be archived and accessible through July 14, 2023, on the Labcorp Investor Relations website.